Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, Ignacio CC, Parkin NT, Petropoulos CJ, Richman DD.

J Virol. 2008 Jun;82(11):5510-8. doi: 10.1128/JVI.02579-07. Epub 2008 Mar 19.


Persistence of primary drug resistance among recently HIV-1 infected adults.

Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, Segal MR, Petropoulos CJ, Grant RM.

AIDS. 2004 Aug 20;18(12):1683-9.


Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.

Hance AJ, Lemiale V, Izopet J, Lecossier D, Joly V, Massip P, Mammano F, Descamps D, Brun-Vézinet F, Clavel F.

J Virol. 2001 Jul;75(14):6410-7.


Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.

Ruff CT, Ray SC, Kwon P, Zinn R, Pendleton A, Hutton N, Ashworth R, Gange S, Quinn TC, Siliciano RF, Persaud D.

J Virol. 2002 Sep;76(18):9481-92.


Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 Pol epitopes.

Mason RD, Bowmer MI, Howley CM, Gallant M, Myers JC, Grant MD.

J Immunol. 2004 Jun 1;172(11):7212-9.


Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection.

de Mendoza C, Martín-Carbonero L, Gallego O, Corral A, González-Lahoz J, Soriano V.

J Med Virol. 2005 May;76(1):1-6.


Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.


Resistance mutations and CTL epitopes in archived HIV-1 DNA of patients on antiviral treatment: toward a new concept of vaccine.

Papuchon J, Pinson P, Lazaro E, Reigadas S, Guidicelli G, Taupin JL, Neau D, Fleury H; Provir/Latitude 45 project.

PLoS One. 2013 Jul 9;8(7):e69029. doi: 10.1371/journal.pone.0069029. Print 2013.


[Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].

Oette M, Kaiser R, Däumer M, Fätkenheuer G, Rockstroh JK, Knechten H, Mitrenga D, Beerenwinkel N, Sagir A, Pfister H, Häussinger D.

Dtsch Med Wochenschr. 2007 May 4;132(18):977-82. German.


In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.

Elbeik T, Hoo BS, Campodonico ME, Dileanis J, Fay FF, Bortolozzi RL, Benetti MS, Fay OH, Marlowe N, Petrauskene O, Chernoff D, Smith L, Ng VL.

J Hum Virol. 2001 Nov-Dec;4(6):317-28.


Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.

Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, Kazmi S, Clarke JR, Johnson GE, Weber JN, Phillips RE.

J Virol. 2003 May;77(10):6041-9.


Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.

Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG, Rachid M, Gracie RS, Chequer-Fernandez SL, Oliveira SM, Arakaki-Sanchez D, Chequer PJ, Morgado MG.

Mem Inst Oswaldo Cruz. 2005 Feb;100(1):73-8. Epub 2005 Apr 12.


HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.

Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D'Aquila RT, Quinn TC, Siliciano JD, Siliciano RF, Persaud D.

JAMA. 2001 Jul 11;286(2):196-207.


Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs.

Alteri C, Svicher V, Gori C, D'Arrigo R, Ciccozzi M, Ceccherini-Silberstein F, Selleri M, Bardacci SA, Giuliani M, Elia P, Scognamiglio P, Balzano R, Orchi N, Girardi E, Perno CF; SENDIH Study Group.

BMC Infect Dis. 2009 Jul 16;9:111. doi: 10.1186/1471-2334-9-111.


Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission.

Delaugerre C, Morand-Joubert L, Chaix ML, Picard O, Marcelin AG, Schneider V, Krivine A, Compagnucci A, Katlama C, Girard PM, Calvez V.

Antivir Ther. 2004 Jun;9(3):415-21.


Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.

Nicastri E, Sarmati L, d'Ettorre G, Palmisano L, Parisi SG, Uccella I, Rianda A, Concia E, Vullo V, Vella S, Andreoni M.

J Med Virol. 2003 Jan;69(1):1-6.


Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy.

Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, Xiang Y, Henely C, Schmetter B, Uy J, van den Berg-Wolf M, Kozal M; Terry Beirn Community Programs for Clinical Research on AIDS 058 Study Team.

Clin Infect Dis. 2005 Feb 1;40(3):468-74. Epub 2005 Jan 10.


[Detection of primary antiretroviral resistance in Chilean patients recently infected with human immunodeficiency virus (HIV)].

Acevedo W, Gallardo AM, Galaz J, Afani A, Cortés E.

Rev Med Chil. 2007 Nov;135(11):1406-13. doi: /S0034-98872007001100006. Epub 2008 Jan 16. Spanish.


Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005-2009.

Youmans E, Tripathi A, Albrecht H, Gibson JJ, Duffus WA.

South Med J. 2011 Feb;104(2):95-101. doi: 10.1097/SMJ.0b013e3181fcd75b.


Supplemental Content

Support Center